STANLEY VINORES

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Pegaptanib in the treatment of wet, age-related macular degeneration
    Stanley A Vinores
    Wilmer Eye Instutute, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287 9289, USA
    Int J Nanomedicine 1:263-8. 2006
  2. pmc Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye
    Hu Huang
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 6:e21411. 2011
  3. pmc Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation
    Xiufeng Zhong
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Mol Vis 17:492-507. 2011
  4. pmc TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage
    Stanley A Vinores
    The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee 825, 600 N Wolfe Street Baltimore, Maryland 21287 9289, United States
    J Neuroimmunol 182:73-9. 2007
  5. ncbi request reprint Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development
    Stanley A Vinores
    Department of Ophthalmology, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9289, USA
    J Cell Physiol 206:749-58. 2006
  6. ncbi request reprint Anecortave (Alcon Laboratories)
    Stanely A Vinores
    825 Maumenee Building, Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287 9289, USA
    IDrugs 8:327-34. 2005
  7. ncbi request reprint Technology evaluation: pegaptanib, Eyetech/Pfizer
    Stanley A Vinores
    Johns Hopkins Hospital, Wilmer Ophthalmological Institute, 825 Maumenee, 600 N Wolfe Street, Baltimore, MD 21287 9289, USA
    Curr Opin Mol Ther 5:673-9. 2003
  8. ncbi request reprint Upregulation of vascular endothelial growth factor (VEGF) in the retinas of transgenic mice overexpressing interleukin-1beta (IL-1beta) in the lens and mice undergoing retinal degeneration
    S A Vinores
    The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287 9289, USA
    Histol Histopathol 18:797-810. 2003
  9. ncbi request reprint Photoreceptor-specific overexpression of platelet-derived growth factor induces proliferation of endothelial cells, pericytes, and glial cells and aberrant vascular development: an ultrastructural and immunocytochemical study
    Stanley A Vinores
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 9289, USA
    Brain Res Dev Brain Res 140:169-83. 2003
  10. ncbi request reprint Experimental models of growth factor-mediated angiogenesis and blood-retinal barrier breakdown
    S A Vinores
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, 825 Maumenee Building, 600 North Wolfe Street, 21287 9289, Baltimore, MD 21287 9289, USA
    Gen Pharmacol 35:233-9. 2000

Research Grants

  1. MEDIATORS OF BLOOD-RETINAL BARRIER BREAKDOWN
    STANLEY VINORES; Fiscal Year: 2001
  2. MEDIATORS OF BLOOD-RETINAL BARRIER BREAKDOWN
    STANLEY VINORES; Fiscal Year: 2002
  3. Potential target molecules for ischemic retinopathies
    STANLEY VINORES; Fiscal Year: 2007
  4. LOCALIZATION OF BLOOD-RETINAL BARRIER BREAKDOWN SITES
    STANLEY VINORES; Fiscal Year: 1992
  5. Potential target molecules for ischemic retinopathies
    STANLEY VINORES; Fiscal Year: 2009
  6. Potential target molecules for ischemic retinopathies
    STANLEY VINORES; Fiscal Year: 2009
  7. MEDIATORS OF BLOOD-RETINAL BARRIER BREAKDOWN
    STANLEY VINORES; Fiscal Year: 2000
  8. LOCALIZATION OF BLOOD-RETINAL BARRIER BREAKDOWN SITES
    STANLEY VINORES; Fiscal Year: 1993
  9. MEDIATORS OF BLOOD RETINAL BARRIER BREAKDOWN
    STANLEY VINORES; Fiscal Year: 1999
  10. Potential target molecules for ischemic retinopathies
    Stanley A Vinores; Fiscal Year: 2010

Collaborators

Detail Information

Publications17

  1. pmc Pegaptanib in the treatment of wet, age-related macular degeneration
    Stanley A Vinores
    Wilmer Eye Instutute, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287 9289, USA
    Int J Nanomedicine 1:263-8. 2006
    ..Further investigation of pegaptanib for the therapy of wet AMD, particularly in combination with other modes of therapy, should be encouraged...
  2. pmc Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye
    Hu Huang
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 6:e21411. 2011
    ..This study evaluates the effects of blocking VEGFR1 and 2 on pathological angiogenesis and vascular leakage in ischemic retinopathy in a model of ROP and in choroidal neovascularization (CNV) in a model of AMD...
  3. pmc Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation
    Xiufeng Zhong
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Mol Vis 17:492-507. 2011
    ..The present study was conducted to evaluate the effect of overexpression of VEGF-B via adeno-associated virus (AAV) gene transfer on ocular angiogenesis, inflammation, and the blood-retinal barrier (BRB)...
  4. pmc TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage
    Stanley A Vinores
    The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee 825, 600 N Wolfe Street Baltimore, Maryland 21287 9289, United States
    J Neuroimmunol 182:73-9. 2007
    ..Ischemia-induced retinal neovascularization, which has previously been shown to require VEGF, does not require TNF-alpha and is unaffected by attenuation of leukostasis...
  5. ncbi request reprint Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development
    Stanley A Vinores
    Department of Ophthalmology, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9289, USA
    J Cell Physiol 206:749-58. 2006
    ..These data suggest that induction of VEGF through the HRE in its promoter is critical for retinal and CNV, but not for retinal vascular development...
  6. ncbi request reprint Anecortave (Alcon Laboratories)
    Stanely A Vinores
    825 Maumenee Building, Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287 9289, USA
    IDrugs 8:327-34. 2005
    ..Anecortave, an angiostatic steroid administered as a posterior juxtascleral depot, is under development by Alcon Laboratories Inc for the potential prevention and treatment of ocular diseases, in particular age-related macular degeneration...
  7. ncbi request reprint Technology evaluation: pegaptanib, Eyetech/Pfizer
    Stanley A Vinores
    Johns Hopkins Hospital, Wilmer Ophthalmological Institute, 825 Maumenee, 600 N Wolfe Street, Baltimore, MD 21287 9289, USA
    Curr Opin Mol Ther 5:673-9. 2003
    ..Gilead was previously investigating the aptamer for the potential treatment of cancer, however, no data have been published for this indication since 1999...
  8. ncbi request reprint Upregulation of vascular endothelial growth factor (VEGF) in the retinas of transgenic mice overexpressing interleukin-1beta (IL-1beta) in the lens and mice undergoing retinal degeneration
    S A Vinores
    The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287 9289, USA
    Histol Histopathol 18:797-810. 2003
    ..The latter peak appears to be related to retinal destruction...
  9. ncbi request reprint Photoreceptor-specific overexpression of platelet-derived growth factor induces proliferation of endothelial cells, pericytes, and glial cells and aberrant vascular development: an ultrastructural and immunocytochemical study
    Stanley A Vinores
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 9289, USA
    Brain Res Dev Brain Res 140:169-83. 2003
    ..Pericytes and glial cells are usually found in clusters and are not associated with the abnormal vessels. The lack of this association may account for the failure to form a mature vasculature...
  10. ncbi request reprint Experimental models of growth factor-mediated angiogenesis and blood-retinal barrier breakdown
    S A Vinores
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, 825 Maumenee Building, 600 North Wolfe Street, 21287 9289, Baltimore, MD 21287 9289, USA
    Gen Pharmacol 35:233-9. 2000
    ..The phenotype suggests that an additional factor is necessary for the maturation and penetration of vascular endothelial cells into the retina to form the deep capillary bed...
  11. ncbi request reprint Vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGFbeta), and interleukin-6 (IL-6) in experimental herpesvirus retinopathy: association with inflammation and viral infection
    S A Vinores
    The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9289, USA
    Histol Histopathol 16:1061-71. 2001
    ....
  12. ncbi request reprint Blood-retinal barrier breakdown in experimental coronavirus retinopathy: association with viral antigen, inflammation, and VEGF in sensitive and resistant strains
    S A Vinores
    825 Maumenee Building, Wilmer Ophthalmologic Institute, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287 9289, USA
    J Neuroimmunol 119:175-82. 2001
    ..Vascular endothelial growth factor (VEGF) is upregulated only in susceptible mice during the secondary (retinal degeneration) phase...
  13. ncbi request reprint Cellular mechanisms of blood-retinal barrier dysfunction in macular edema
    S A Vinores
    The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Doc Ophthalmol 97:217-28. 1999
    ..To determine the mechanism of blood-retinal barrier (BRB) dysfunction in human and experimental specimens using immunocytochemistry...
  14. ncbi request reprint EMAP cytokine expression in developing retinas of normal and retinal degeneration (rd) mutant mice
    S H Liu
    Wilmer Eye Institute, Johns Hopkins University School of Medicine, 467 Woods Building, Baltimore, MD 21205, USA
    J Neuroimmunol 114:28-34. 2001
    ..The increased expression of EMAP precursor levels in rd mouse retina may reflect the enhanced rate of translation and protein synthesis in the production of endogenous factors that promote survival in the GCL and INL...
  15. ncbi request reprint Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells
    P A Campochiaro
    Wilmer Institute, Johns Hopkins Hospital, Baltimore, MD 21287 9277
    J Cell Sci 107:2459-69. 1994
    ..These data suggest that PDGF is an autocrine stimulator of growth in RPE that plays a role in retinal wound repair and epiretinal membrane formation...
  16. ncbi request reprint Class III beta-tubulin in human retinal pigment epithelial cells in culture and in epiretinal membranes
    S A Vinores
    Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287 9289, USA
    Exp Eye Res 60:385-400. 1995
    ..These findings demonstrate that mature human RPE cells have the capacity to express a neuron-associated gene in response to conditions that promote dedifferentiation...
  17. pmc Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment
    M S Seo
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Am J Pathol 157:995-1005. 2000
    ..They also provide a new model of traction retinal detachment that can be used to investigate new treatments for patients with proliferative retinopathies...

Research Grants16

  1. MEDIATORS OF BLOOD-RETINAL BARRIER BREAKDOWN
    STANLEY VINORES; Fiscal Year: 2001
    ....
  2. MEDIATORS OF BLOOD-RETINAL BARRIER BREAKDOWN
    STANLEY VINORES; Fiscal Year: 2002
    ....
  3. Potential target molecules for ischemic retinopathies
    STANLEY VINORES; Fiscal Year: 2007
    ..If multiple target molecules are identified, combination therapies can be devised to provide maximum therapeutic effectiveness while minimizing adverse effects. ..
  4. LOCALIZATION OF BLOOD-RETINAL BARRIER BREAKDOWN SITES
    STANLEY VINORES; Fiscal Year: 1992
    ..These experiments could provide new insights concerning the BRB and how it might be modulated, which could serve as a basis of the design of new treatment approaches for macular edema...
  5. Potential target molecules for ischemic retinopathies
    STANLEY VINORES; Fiscal Year: 2009
    ..If multiple target molecules are identified, combination therapies can be devised to provide maximum therapeutic effectiveness while minimizing adverse effects. ..
  6. Potential target molecules for ischemic retinopathies
    STANLEY VINORES; Fiscal Year: 2009
    ..If multiple target molecules are identified, combination therapies can be devised to provide maximum therapeutic effectiveness while minimizing adverse effects. ..
  7. MEDIATORS OF BLOOD-RETINAL BARRIER BREAKDOWN
    STANLEY VINORES; Fiscal Year: 2000
    ....
  8. LOCALIZATION OF BLOOD-RETINAL BARRIER BREAKDOWN SITES
    STANLEY VINORES; Fiscal Year: 1993
    ..These experiments could provide new insights concerning the BRB and how it might be modulated, which could serve as a basis of the design of new treatment approaches for macular edema...
  9. MEDIATORS OF BLOOD RETINAL BARRIER BREAKDOWN
    STANLEY VINORES; Fiscal Year: 1999
    ..This proposal could provide important new information concerning the pathogenesis of macular edema and provide new avenues for therapeutic intervention. ..
  10. Potential target molecules for ischemic retinopathies
    Stanley A Vinores; Fiscal Year: 2010
    ..If multiple target molecules are identified, combination therapies can be devised to provide maximum therapeutic effectiveness while minimizing adverse effects. ..